v3.26.1
Segment Information (Details)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
segment
Jun. 30, 2025
USD ($)
Segment Reporting [Line Items]        
Number of operating segments | segment     1  
Number of reportable segments | segment     1  
Provision for income taxes $ 391 $ 261 $ 663 $ 870
Net loss 137,311 198,147 267,843 419,824
Operating Segments | Reportable Segment        
Segment Reporting [Line Items]        
Preclinical research programs R&D Expense 7,730 16,398 16,279 41,933
R&D personnel expense (excluding share-based compensation) 19,421 20,490 40,433 41,627
R&D Share-based compensation expense 11,983 13,110 30,458 48,344
G&A personnel expense (excluding share-based compensation) 5,765 6,004 11,220 12,478
G&A Share-based compensation expense 7,181 7,702 16,992 25,530
Other segment items 15,736 20,706 30,191 37,660
Non-operating expense (income) 12,021 (13,815) 11,853 (14,308)
Provision for income taxes 391 261 663 870
Net loss 137,311 198,147 267,843 419,824
Operating Segments | BHV-4157 (Troriluzole) | Reportable Segment        
Segment Reporting [Line Items]        
Direct R&D program expense 7,704 14,245 14,626 28,033
Operating Segments | BHV-2000 (Taldefgrobep Alfa) | Reportable Segment        
Segment Reporting [Line Items]        
Direct R&D program expense 5,730 8,045 15,062 14,229
Operating Segments | BHV-7000 & BHV-7010 (Kv7) | Reportable Segment        
Segment Reporting [Line Items]        
Direct R&D program expense 13,845 31,172 33,578 62,744
Operating Segments | BHV-2100 & BHV-2110 (TRPM3 Antagonist) | Reportable Segment        
Segment Reporting [Line Items]        
Direct R&D program expense (325) 6,845 (530) 23,594
Operating Segments | BHV-8000 (TYK2/JAK1) | Reportable Segment        
Segment Reporting [Line Items]        
Direct R&D program expense 4,142 21,216 9,312 25,589
Operating Segments | BHV-1300 (IgG Degrader) | Reportable Segment        
Segment Reporting [Line Items]        
Direct R&D program expense 9,861 11,732 11,003 20,352
Operating Segments | BHV-1310 (IgG Degrader) | Reportable Segment        
Segment Reporting [Line Items]        
Direct R&D program expense 15 3,612 (19) 4,686
Operating Segments | BHV-1400 (IgA Degrader) | Reportable Segment        
Segment Reporting [Line Items]        
Direct R&D program expense 11,709 6,737 16,846 11,597
Operating Segments | BHV-1600 (β1-AR AAB Degrader) | Reportable Segment        
Segment Reporting [Line Items]        
Direct R&D program expense (288) 1,806 (99) 4,809
Operating Segments | BHV-1510 (TROP-2) | Reportable Segment        
Segment Reporting [Line Items]        
Direct R&D program expense 2,465 5,384 6,502 9,873
Operating Segments | BHV-1530 (FGFR3) | Reportable Segment        
Segment Reporting [Line Items]        
Direct R&D program expense 2,211 15,393 3,410 18,569
Operating Segments | Other R&D program expense | Reportable Segment        
Segment Reporting [Line Items]        
Direct R&D program expense 14 1,104 63 1,615
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment        
Segment Reporting [Line Items]        
Net loss $ 0 $ 0 $ 0 $ 0